MannKind Corporation (NASDAQ:MNKD) is reporting third quarter financial results on Wednesday 4th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, MNKD is expected to report 3Q20 loss of $ 0.05 per share from revenue of $ 15.56 million.
For the full year, analysts anticipate top line of $ 63.65 million, while looking forward to loss of $ 0.18 per share bottom line.
Previous Quarter Performance
MannKind Corporation unwinded loss for the second quarter of $ 0.05 per share, from the revenue of $ 15.11 million. Wall street analysts are predicting, MNKD to report 2Q20 loss of $ 0.05 per share from revenue of $ 14.76 million. The top line results outshined analysts by $ 0.35 million or 2.37 percent.
Stock Performance
Shares of MannKind Corporation traded up $ 0.05 or 2.50 percent on Tuesday, reaching $ 2.05 with volume of 2.19 million shares. MannKind Corporation has traded high as $ 2.07 and has cracked $ 2.00 on the downward trend
According to the previous trading day, closing price of $ 2.05, representing a 150.00 % increase from the 52 week low of $ 0.80 and a 19.35 % decrease over the 52 week high of $ 2.48.
The company has a market capital of $ 469.81 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
MannKind Corporation will be hosting a conference call at 5:00 PM eastern time on 4th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.mannkindcorp.com
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company has a licensing and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension.
